News | March 08, 2022
Moderna to set up first mRNA facility in Kenya
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Collaboration in the industry needs to be institutionalised to drive the growth.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
It is being developed by Pune-based Gennova Biopharmaceuticals
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
Subscribe To Our Newsletter & Stay Updated
